Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.03 EUR
−16.96 M EUR
9.47 M EUR
17.24 M
About NEWRON PHARMA N
Sector
CEO
Stefan Weber
Headquarters
Bresso
Website
Founded
2002
ISIN
IT0004147952
FIGI
BBG002K2RNF2
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The firm's products include Xadago (safinamide), Evenamide (NW-3509) and Ralfinamide. The company was founded by Luca Benatti, Ruggero Fariello and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of NP5 is 8.57 EUR — it has increased by 1.66% in the past 24 hours. Watch NEWRON PHARMACEUT. EO-,20 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange NEWRON PHARMACEUT. EO-,20 stocks are traded under the ticker NP5.
NP5 stock has fallen by −2.50% compared to the previous week, the month change is a 9.03% rise, over the last year NEWRON PHARMACEUT. EO-,20 has showed a 86.30% increase.
We've gathered analysts' opinions on NEWRON PHARMACEUT. EO-,20 future price: according to them, NP5 price has a max estimate of 14.61 EUR and a min estimate of 14.61 EUR. Watch NP5 chart and read a more detailed NEWRON PHARMACEUT. EO-,20 stock forecast: see what analysts think of NEWRON PHARMACEUT. EO-,20 and suggest that you do with its stocks.
NP5 stock is 1.63% volatile and has beta coefficient of 1.68. Track NEWRON PHARMACEUT. EO-,20 stock price on the chart and check out the list of the most volatile stocks — is NEWRON PHARMACEUT. EO-,20 there?
Today NEWRON PHARMACEUT. EO-,20 has the market capitalization of 176.29 M, it has decreased by −3.02% over the last week.
Yes, you can track NEWRON PHARMACEUT. EO-,20 financials in yearly and quarterly reports right on TradingView.
NEWRON PHARMACEUT. EO-,20 is going to release the next earnings report on Mar 18, 2025. Keep track of upcoming events with our Earnings Calendar.
NP5 net income for the last half-year is −9.54 M EUR, while the previous report showed −9.56 M EUR of net income which accounts for 0.14% change. Track more NEWRON PHARMACEUT. EO-,20 financial stats to get the full picture.
No, NP5 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NEWRON PHARMACEUT. EO-,20 EBITDA is −14.76 M EUR, and current EBITDA margin is −126.18%. See more stats in NEWRON PHARMACEUT. EO-,20 financial statements.
Like other stocks, NP5 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NEWRON PHARMACEUT. EO-,20 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NEWRON PHARMACEUT. EO-,20 technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NEWRON PHARMACEUT. EO-,20 stock shows the buy signal. See more of NEWRON PHARMACEUT. EO-,20 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.